The Peptide Risks That Hit Women Differently — What Two Academic Researchers Actually Found
Women have a 1.5-2x higher adverse drug reaction rate than men. Two Lancaster University researchers laid out specific, sex-relevant risks in ipamorelin, CJC-1295, TB-500, and GHK-Cu that most peptide guides don't mention.
Most peptide safety content is written as if one body covers everyone. It doesn't. Writing in The Conversation (July 2026), Adam Taylor (Professor of Anatomy) and Michelle Swainson (Lecturer in Physiology), both at Lancaster University, laid out several sex-specific risks in unregulated peptides that most guides simply don't mention — including some of the exact compounds most commonly discussed for women's use.
Why the Baseline Risk Is Already Higher
Women experience adverse drug reactions at roughly 1.5 to 2 times the rate of men — partly because women take prescription medicines more overall, and partly because of real pharmacokinetic and hormonal differences in how drugs are processed. That's the backdrop the researchers frame the rest of their concerns against, not a standalone scare stat.
Ipamorelin & CJC-1295: The Ovarian-Axis Concern
Both compounds work by sustaining elevated growth hormone and IGF-1 levels for days at a time. According to Taylor and Swainson, that sustained elevation has been linked to swelling and fluid retention, and — specific to women — hormonal imbalances, disruption to ovarian function, and a higher risk of miscarriage. See our Ipamorelin and CJC-1295 pages for the existing human trial data and what's actually established there.
TB-500: What "Turned Up in Cancer Cells" Actually Means
TB-500 (synthetic Thymosin Beta-4) is marketed for tissue repair and reduced inflammation. The researchers note it "has also turned up in several cancers, including breast cancer cells and some common forms of lung cancer" — worth being precise that this is an association found in cancer cells, not a demonstrated cause-and-effect claim. It does line up with something we already flag on our own TB-500 page: TB-500/Thymosin Beta-4 is reported on the FDA's bulk drug substances list as a substance presenting significant safety risk for compounding — two independent sources pointing at the same compound.
GHK-Cu: A Pregnancy-Specific Warning
For GHK-Cu specifically, the researchers flag a pregnancy-specific risk with the injectable route: excess copper has been linked to restricted growth in the womb and neurological problems in the baby. Our GHK-Cu page covers the compound's real (thin) human safety data generally — this is a more specific warning worth knowing on top of that.
The Injection-Site Detail Nobody Mentions
One genuinely practical point from the piece: women's fat distribution means less of a fatty buffer in the abdomen, which the researchers say makes stomach injections riskier there specifically than the same injection site would be for a man. Not alarmist — just a real anatomical difference most dosing guidance never accounts for.
The Point of Writing This
None of this is a reason to panic, and none of it means these compounds are automatically off the table — it's a reason to know the specific, sex-relevant risk before deciding anything, rather than reading a generic unisex side-effects list and assuming it's complete. For the fuller context on how to weigh evidence quality across any compound's side-effects data, see how to actually read a side effects section. Full source: Taylor & Swainson, The Conversation, July 2026.